Da Zen Theranostics

Executive Summary

Da Zen Theranostics is a private biotechnology company headquartered in San Diego, CA, founded in 2018. The company specializes in developing integrated theranostic platforms that pair diagnostic tools with targeted therapeutics to enable personalized cancer treatment. By identifying specific biomarkers in a patient's tumor, Da Zen aims to deliver precisely matched therapies, potentially improving outcomes and reducing side effects compared to conventional approaches. While the company operates in the high-growth precision oncology space, its early-stage status means limited public information on specific pipeline candidates or financial backing. The theranostics market is increasingly competitive, with established players in both diagnostics and therapeutics, but Da Zen's integrated approach could offer differentiation if clinical validation is achieved. The company's success hinges on advancing its platform through preclinical or early clinical milestones, securing partnerships or funding, and demonstrating clinical utility in biomarker-driven patient selection.

Upcoming Catalysts (preview)

• 2027Lead program entry into Phase I clinical trials30% success
• 2026Strategic partnership or licensing deal with a larger pharma or diagnostic company40% success
• 2026Series A or B funding round to support platform development50% success